Biotricity Inc

Good afternoon, and welcome to Biotricity's third quarter fiscal 2024 financial results and business update conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Deborah Chen of Investor Relations. Please go ahead, ma'am.

Good afternoon, everyone, and welcome to Biotricity's third quarter fiscal 2024 earnings conference call. As a reminder, Biotricity's third quarter 2024 fiscal year ended December 31st, 2023, so all figures presented for this period will reflect that end date. Earlier, Biotricity issued its fiscal 2024 third quarter press release, which highlighted financial and operational results. A copy of the press release is available on the investor relations section of Biotricity's website, and the full financials have been filed with the SEC on Form 10-Q and posted on EDGAR at www.sec.gov. Before beginning the company's formal remarks, I'd like to remind listeners that today's discussion may contain forward-looking statements that reflect management's current views with respect to future events. Any such statements are subject to risk and uncertainties that can cause actual results to differ materially from those projected in the forward-looking statements. Biotricity does not undertake to update any forward-looking statements except as required. At this point, I'm pleased to turn the call over to Biotricity's founder and CEO, Dr. Waqas Al-Siddiq. Please go ahead.

Thank you, Deborah, and thank you, everybody, for joining us today. This quarter proved to be quite successful for us. Despite limited news announcements, our diligence and focus efforts can be seen across various operational and financial metrics. We not only improved our margins once again, but also achieved record margins, increased our revenue, and reduced losses. This brings us closer towards our path to profitability, and I believe that time has never been nearer. We continue to leverage our data intelligently, pushing the boundaries of operational automation and efficiency, and in late January, we announced the development of our Cardiac AI Cloud platform. The platform is being designed for predictive monitoring, helping physicians and users in detecting potential issues before they arise. This supports our objective for early interventions, which decreases the likelihood of readmissions and contributes to lowering healthcare costs. Biotricity's product portfolio is already recognized as one of the most extensive remote cardiac monitoring collections worldwide, and this further reinforces our commitment to advance healthcare solutions. Today, we have successfully recorded over 500 billion heartbeats, a data set that is supporting our R&D efforts to continuously improve analytics to help drive better patient outcomes. Additionally, we were proud to announce that to date we have monitored, recorded, and helped diagnose over 250,000 patients. Some additional features that further enhance our existing products include faster analytical results, improved scalability, improved operational efficiency, and support for other commercial models. Our efforts to build a comprehensive cardiac AI cloud are the first step in making cardiac care not only accessible, but also affordable and scalable. Today, cardiologists are overwhelmed with too many patients and too much data, making it difficult for them to service more patients. An accurate cardiac cloud will provide the necessary support and assistance to cardiologists so that they can service more patients and focus on the most relevant pieces of data. I believe that we have the ability to transform cardiac care into a more streamlined and effective healthcare solution. Results for our third quarter demonstrate year-over-year revenue growth and improvements in all key operating metrics specifically in recurring technology fees, device sales, and gross margins. Throughout this, we've maintained a strong focus on cost control, managing expenses, and making consistent progress towards our goal of achieving positive cash flow and profitability. We've upheld our track record of strong customer retention, supported by the quality of our customers and the cardiologist-friendly support services that emphasize the accuracy of our diagnostics and ease of use. Our recurring technology fees and gross margins continue to trend upward, and we have successfully managed expenses, all while penetrating the market and securing market leadership in cardiac remote patient monitoring devices and solutions. In looking forward, we plan to leverage our sales force to expand and penetrate new markets. With that, I'll turn the call over to our CFO, John Iannoglou.